SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agenus (AGEN)
AGEN 3.960-0.3%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Dodgy Ticker who wrote (58)12/7/2005 11:05:39 AM
From: scaram(o)uche  Read Replies (2) of 146
 
Bob:

As you know, FDA doesn't tell a company whether or not a pivotal trial is a good trial, whether or not the design will be sufficient for approval. They simply look at safety data and give an ok if that data looks clean and there's a need.

If the RCC trial is positive? If the vaccine is shown to provide modest protection?

Which component is it that might cause that protection, the hsp or the "self" component (distinct cancer antigen, derived from the cancer)?

Has someone at agen told you that the hsp component, alone, won't/can't lead to modest protection? TIA for any help.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News